NYSE · INCY
Healthcare · Biotechnology
$121.74
Up+$1.16 (+0.95%)
Updated Sep 16, 2026, 3:25 PM
SID Score
7.2/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
INCY closed at $121.74 after 20 trading sessions, down 1.40% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $121.58 | $122.19 | $119.97 | $121.74 | 1.56M |
| Sep 14, 2026 | $122.48 | $123.345 | $121.28 | $122.19 | 1.46M |
| Sep 11, 2026 | $124.35 | $124.35 | $121.42 | $121.47 | 1.43M |
| Sep 10, 2026 | $125.09 | $126.31 | $122.58 | $123.28 | 1.46M |
| Sep 9, 2026 | $125.66 | $127.72 | $123.57 | $126.01 | 1.3M |
| Sep 8, 2026 | $124.105 | $126.40 | $122.222 | $124.40 | 1.28M |
| Sep 4, 2026 | $126.46 | $128.08 | $126.04 | $126.75 | 1.04M |
| Sep 3, 2026 | $129.67 | $130.00 | $126.2001 | $128.00 | 910.23K |
| Sep 2, 2026 | $126.43 | $129.56 | $125.89 | $128.83 | 2.32M |
| Sep 1, 2026 | $124.61 | $125.1392 | $122.50 | $125.01 | 1.19M |
| Aug 31, 2026 | $122.66 | $124.00 | $121.61 | $123.22 | 1.48M |
| Aug 28, 2026 | $127.74 | $127.74 | $123.08 | $124.37 | 1.22M |
| Aug 27, 2026 | $128.13 | $128.20 | $126.06 | $127.74 | 700.68K |
| Aug 26, 2026 | $129.18 | $129.535 | $127.7701 | $128.12 | 800.28K |
| Aug 25, 2026 | $128.975 | $130.80 | $127.50 | $129.72 | 1.16M |
| Aug 24, 2026 | $127.47 | $128.36 | $126.31 | $127.98 | 799.61K |
| Aug 21, 2026 | $126.45 | $129.92 | $125.60 | $127.81 | 1.37M |
| Aug 20, 2026 | $127.10 | $129.80 | $126.71 | $127.22 | 1.21M |
| Aug 19, 2026 | $125.00 | $129.56 | $124.595 | $128.47 | 1.59M |
| Aug 18, 2026 | $124.29 | $124.74 | $123.23 | $123.47 | 1.19M |
The latest Smart Investors Daily articles mentioning INCY.
INCY research
Company profile and research snapshot.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | Canaccord Genuity | Buy | — |
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Mizuho | Outperform | — |
| Aug 3, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Incyte stock is trading just below a buy zone just as Big Money is giving it the stamp of approval. Shares popped in July following a strong earnings report that impressed investors. Incyte stock shows an ideal Composite Rating of 99, boosted by steady year-over-year earnings growth and a decent Relative Strength Rating of 88.
Benzinga · Sep 11, 2026
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of $24.69 billion.
Yahoo · Sep 10, 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Yahoo · Sep 10, 2026
Incyte (NYSE: INCY) today announced that MINJUVI® (tafasitamab) in the treatment of relapsed or refractory follicular lymphoma (R/R FL) has been funded in the province of Ontario through Ontario's Funding Accelerated for Specific Treatments (FAST) Program. Through this program, eligible patients may gain access to treatment sooner while formal reimbursement processes continue.1,2
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INCY.
